FDA approves J&J prostate cancer treatment

Posted on


  1. FDA approves J&J prostate cancer treatment  Reuters
  2. FDA Approves First Treatment for Non-Metastatic, Castration-Resistant Prostate Cancer  Regulatory Focus
  3. FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer  AJMC.com Managed Markets Network
  4. Full coverage

Image Result For Fda Approves J

Image Result For Fda Approves J



Days ago Reuters The U.S. Food and Drug Administration on Wednesday approved Johnson Johnson's Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy. The approval comes when Johnson Johnson's blockbuster prostate . On , the U.S. Food and Drug Administration approved neratinib NERLYNX, Puma Biotechnology, Inc. for the extended adjuvant treatment of adult patients with early stage HER overexpressed amplified breast cancer, to follow adjuvant trastuzumab based therapy. Approval was based on . The U.S. Food and Drug Administration today approved Besponsa inotuzumab ozogamicin for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia ALL . The safety and efficacy of Besponsa were stu.d in a randomized trial of patients . The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life threatening diseases..







Leave a Reply

Your email address will not be published. Required fields are marked *